Valion Bio, Inc. Common Stock (NASDAQ:VBIO) Posts Quarterly Earnings Results, Beats Expectations By $405.83 EPS

Valion Bio, Inc. Common Stock (NASDAQ:VBIO) released its earnings results on Friday. The company reported ($2.17) earnings per share for the quarter, topping analysts’ consensus estimates of ($408.00) by $405.83, FiscalAI reports.

Valion Bio, Inc. Common Stock Stock Performance

Valion Bio, Inc. Common Stock stock traded up $0.02 during midday trading on Friday, hitting $0.19. The company’s stock had a trading volume of 169,670,743 shares, compared to its average volume of 2,503,005. The company has a market cap of $790,990.00, a price-to-earnings ratio of -0.03 and a beta of 1.85. The company has a debt-to-equity ratio of 0.62, a current ratio of 3.31 and a quick ratio of 3.02. The company has a 50-day moving average price of $0.45 and a two-hundred day moving average price of $0.78. Valion Bio, Inc. Common Stock has a 1-year low of $0.16 and a 1-year high of $5.60.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Valion Bio, Inc. Common Stock in a report on Friday, July 17th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the company has an average rating of “Sell”.

About Valion Bio, Inc. Common Stock

Tivic Health Systems is a commercial-stage medical technology company that develops and markets non-drug, neuromodulation-based therapies for nasal and sinus health. The company’s solutions are designed to alleviate sinus pain, pressure and congestion through gentle microcurrent and vibration stimulation. By targeting the underlying nerve pathways in the nasal passages, Tivic Health aims to provide an alternative to over-the-counter and prescription medications without introducing systemic side effects.

The flagship product, ClearUP™ Sinus Pain Relief, is an FDA-cleared, hand-held device intended for home use.